Overview

Eutropics is committed to providing patient-specific tumor susceptibility information for guiding the treatment of hematologic malignancies including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). Use of our proprietary platform provides important insight into an individual patient’s cancer that enables the practical exercise of personalized medicine. Eutropics’ technology also provides an important biomarker for guided cancer drug development.